128 related articles for article (PubMed ID: 824066)
1. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies.
Desnick RJ; Blieden LC; Sharp HL; Hofschire PJ; Moller JH
Circulation; 1976 Nov; 54(5):818-25. PubMed ID: 824066
[TBL] [Abstract][Full Text] [Related]
2. Cardiac manifestations in Fabry disease.
Linhart A; Lubanda JC; Palecek T; Bultas J; Karetová D; Ledvinová J; Elleder M; Aschermann M
J Inherit Metab Dis; 2001; 24 Suppl 2():75-83; discussion 65. PubMed ID: 11758683
[TBL] [Abstract][Full Text] [Related]
3. The heart in Anderson Fabry disease.
Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal glycosphingolipid storage in chloroquine-induced alpha-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease.
Inagaki M; Katsumoto T; Nanba E; Ohno K; Suehiro S; Takeshita K
Acta Neuropathol; 1993; 85(3):272-9. PubMed ID: 8384772
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement in Fabry endothelial cells and fibroblasts: uptake experiments and electron microscopical studies.
Hasholt L; Wandall A; Sørensen SA
Clin Genet; 1988 May; 33(5):360-71. PubMed ID: 2837353
[TBL] [Abstract][Full Text] [Related]
8. [Fabry disease: systemic deposition of a glycolipid].
Sela BA; Pavlotsky F; Trau H; Kaplan B; Polak-Charcon S; Engelberg S
Harefuah; 1994 Sep; 127(5-6):157-60, 215. PubMed ID: 7995582
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits.
Kanda A; Nakao S; Tsuyama S; Murata F; Kanzaki T
Virchows Arch; 2000 Jan; 436(1):36-42. PubMed ID: 10664160
[TBL] [Abstract][Full Text] [Related]
10. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.
Van Loo A; Vanholder R; Madsen K; Praet M; Kint J; De Paepe A; Messiaen L; Lameire N; Hasholt L; Sørensen SA; Ringoir S
Am J Nephrol; 1996; 16(4):352-7. PubMed ID: 8739292
[TBL] [Abstract][Full Text] [Related]
11. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.
Takenaka T; Teraguchi H; Yoshida A; Taguchi S; Ninomiya K; Umekita Y; Yoshida H; Horinouchi M; Tabata K; Yonezawa S; Yoshimitsu M; Higuchi K; Nakao S; Anan R; Minagoe S; Tei C
J Cardiol; 2008 Feb; 51(1):50-9. PubMed ID: 18522775
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients.
Navarro C; Teijeira S; Dominguez C; Fernandez JM; Rivas E; Fachal C; Barrera S; Rodriguez C; Iranzo P
Acta Neuropathol; 2006 Feb; 111(2):178-85. PubMed ID: 16463201
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional changes in peripheral vasculature of Fabry patients.
Kalliokoski RJ; Kalliokoski KK; Penttinen M; Kantola I; Leino A; Viikari JS; Simell O; Nuutila P; Raitakari OT
J Inherit Metab Dis; 2006 Oct; 29(5):660-6. PubMed ID: 16906474
[TBL] [Abstract][Full Text] [Related]
14. Renal accumulation of glycosphingolipids. Report of a case and a review of literature.
Miyasaki K
Nephron; 1975; 14(6):456-65. PubMed ID: 807860
[TBL] [Abstract][Full Text] [Related]
15. Renal ultrastructural findings in Anderson-Fabry disease.
Sessa A; Toson A; Nebuloni M; Pallotti F; Giordano F; Battini G; Maglio A; Meroni M; Calconi G; Bertolone G; Gatti P
J Nephrol; 2002; 15(2):109-12. PubMed ID: 12018625
[TBL] [Abstract][Full Text] [Related]
16. [End-stage cardiac manifestations and autopsy findings in patients with cardiac fabry disease].
Teraguchi H; Takenaka T; Yoshida A; Taguchi S; Ninomiya K; Yoshida H; Horinouchi M; Yonezawa S; Nakao S; Minagoe S; Tei S
J Cardiol; 2004 Feb; 43(2):98-9. PubMed ID: 15046052
[TBL] [Abstract][Full Text] [Related]
17. B.C.P. Jansen Institute, University of Amsterdam, Amsterdam, The Netherlands.
Van den Bergh FA; Rietra PJ; Kolk-Vegter AJ; Bosch E; Tager JM
Acta Med Scand; 1976; 200(4):249-56. PubMed ID: 824932
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy.
Shah JS; Elliott PM
Acta Paediatr Suppl; 2005 Mar; 94(447):11-4; discussion 9-10. PubMed ID: 15895705
[TBL] [Abstract][Full Text] [Related]
19. Quantitative evaluation of sphingolipids using delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry with sphingosylphosphorylcholine as an internal standard. Practical application to cardiac valves from a patient with Fabry disease.
Fujiwaki T; Tasaka M; Takahashi N; Kobayashi H; Murakami Y; Shimada T; Yamaguchi S
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 832(1):97-102. PubMed ID: 16431168
[TBL] [Abstract][Full Text] [Related]
20. [Biochemical and pathological studies on a carrier of Fabry's disease manifesting bouts of pain in the extremities].
Katayama M; Kobayashi T; Ohnishi A; Goto I; Kuroiwa Y
Rinsho Shinkeigaku; 1984 Jun; 24(6):575-80. PubMed ID: 6094070
[No Abstract] [Full Text] [Related]
[Next] [New Search]
